Get started
Author

Daiki Kanaoka

Observed name: D. Kanaoka
ORCID: 0000-0003-0696-062X
Observed ORCID: 0000-0003-0696-062X
OpenAlex ID: A5088404135
Inhibition of T-type calcium channels and hydrogen sulfide-forming enzyme reverses paclitaxel-evoked neuropathic hyperalgesia in rats
2011 · K. Okubo, T. Takahashi, et al. · Neuroscience · 122
Endogenous and exogenous hydrogen sulfide facilitates T-type calcium channel currents in Cav3.2-expressing HEK293 cells
2014 · Fumiko Sekiguchi, Yosuke Miyamoto, et al. · Biochemical and Biophysical Research Communications · 58
AKAP ‐dependent sensitization of Ca v3.2 channels via the EP 4receptor/c AMP pathway mediates PGE 2‐induced mechanical hyperalgesia
2012 · Fumiko Sekiguchi, Yuka Aoki, et al. · British Journal of Pharmacology · 43
PDF
Therapeutic potential of RQ-00311651, a novel T-type Ca2+ channel blocker, in distinct rodent models for neuropathic and visceral pain
2016 · Fumiko Sekiguchi, Yuma Kawara, et al. · Pain · 34
FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al. · Cancer Research Communications · 8
PDF
Design, synthesis, and evaluation of a novel protein degrader FPFT-2216
2025 · Yasuyuki Ueda, Takashi Ando, et al. · Bioorganic & Medicinal Chemistry Letters · 6
TABLE 1 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
FIGURE 1 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
TABLE 2 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
FIGURE 4 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
Figure S4 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
Figure S1 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
FIGURE 2 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
FIGURE 3 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
Figure S2 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
Data from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
Table S3 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
PDF
Table S1 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
PDF
Table S2 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
PDF
Figure S3 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
Table S5 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
PDF
FIGURE 5 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
Table S4 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
PDF
Data from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024 · Daiki Kanaoka, Mitsuo Yamada, et al.
P70 Involvement of endogenous hydrogen sulfide and T-type calcium channels in cyclic AMP-induced neuronal differentiation in ng108-15 cells
2014 · Fumiko Sekiguchi, Yuki Takeda, et al. · Nitric Oxide
Works count: 25
Citation count: 271
H-index: 6
I10-index: 4
Year
Topic
Type